Performance of a Multifocal Contact Lens - Presbyopia Study

NCT ID: NCT02450747

Last Updated: 2018-06-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a four week study to evaluate the performance of a multifocal contact lens in habitual wearers of silicone hydrogel multifocal contact lenses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Presbyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multifocal Test Contact Lens

Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.

Group Type EXPERIMENTAL

etafilcon A MULTIFOCAL

Intervention Type DEVICE

Subjects will wear the test lens for four weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

etafilcon A MULTIFOCAL

Subjects will wear the test lens for four weeks.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adult males or females age 40 to 70 and has full legal capacity to volunteer.
2. The subject is a current spherical silicone hydrogel multifocal (SiHy) contact lens wearer (defined as a minimum of 2 days per week for at least 6 hours of Daily Wear contact lenses, for a minimum of one month prior to the study) and willing to wear the study lenses on a daily basis (defined as a minimum of 6 hours of wear per day) for the duration of the study.
3. The subject must own a pair of wearable spectacles to wear when they cannot wear the study lenses.
4. The subject's optimal vertexed spherical equivalent distance correction must be between +3.50 and -5.50 Diopters (D) (inclusive) in both eyes.
5. Subjective refraction cylinder power must be less than or equal to 0.75 D in both eyes.
6. Requires a reading addition of +0.75 D to +2.50 D in each eye.
7. The subject must have distance and near visual acuity best correctable to logMAR 0.1 (20/25) or better at both distance and near with subjective refraction for each eye.
8. The subject must read and sign the Informed Consent form.
9. The subject must appear able and willing to adhere the instructions set forth in this clinical protocol.

Exclusion Criteria

1. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
2. Participant in unrelated research clinical trial within 30 days prior to enrollment;
3. Known to have any infectious disease (e.g.hepatitis, tuberculosis) or a contagious immunosuppressive disease.
4. Women who are pregnant or lactating or planning a pregnancy at the time of enrollment;
5. Ocular or systemic allergies or disease which might interfere with contact lens wear;
6. Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes.
7. Systemic disease or use of medication which might interfere with contact lens wear;
8. Any corneal distortion;
9. Has any known active\* ocular disease and/or infection;
10. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; and only uses rewetting drops on an occasional basis( greater than 2 times per week).
11. Is a habitual monovision contact lens wearer wearing contact lenses on extended wear basis or for the past 6 months;
12. Diagnosed with Diabetes;
13. Is aphakic; or Has entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions.
14. Has undergone refractive error surgery;
15. Has amblyopia or strabismus;
16. Has anisometropia \>2 D between both eyes;
17. Has a known sensitivity to the diagnostic pharmaceuticals to be used in the study;
18. Any grade 3.0 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear;
19. Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Waterloo, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR-5692

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.